The Cyclops for pulmonary delivery of aminoglycosides; A new member of the Twincer™ family

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 90, Issue , 2015, Pages 8-15

  Hoppentocht, M ^a   Akkerman, O W ^b   Hagedoorn, P ^a   Frijlink, H W ^a   De Boer, A H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Aminoglycosides; Antibiotics; Cystic fibrosis; Disposable inhaler; Dry powder dispersion; High drug dose; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; KANAMYCIN; TOBRAMYCIN; AMINOGLYCOSIDE; EXCIPIENT; MINOCYCLINE; POWDER;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BRONCHIECTASIS; CYSTIC FIBROSIS; DISPOSABLE EQUIPMENT; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRY POWDER; DRY POWDER INHALER; HUMAN; NETHERLANDS; PARTICLE SIZE; RESPIRATORY TRACT INFECTION; SCANNING ELECTRON MICROSCOPY; SPECTROPHOTOMETRY; SPRAY DRYING; TUBERCULOSIS; UNIVERSITY; WATER CONTENT; ADMINISTRATION AND DOSAGE; CHEMISTRY; DRUG FORMULATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; NEBULIZER; PHARMACEUTICS; POWDER; PROCEDURES;

ADMINISTRATION, INHALATION; AMINOGLYCOSIDES; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EXCIPIENTS; LUNG; MINOCYCLINE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; TECHNOLOGY, PHARMACEUTICAL; TOBRAMYCIN;

EID: 84922657302     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.01.012     Document Type: Article

References (25)

1. H. Heijerman, E. Westerman, S. Conway, and D. Touw Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus J. Cyst. Fibros. 8 2009 295 315 10.1016/j.jcf.2009.04.005
2. M. Karvouniaris, D. Makris, A. Triantaris, and E. Zakynthinos Inhaled antibiotics for nosocomial pneumonia Inflamm. Allergy-Drug Targets 11 2012 116 123 10.2174/187152812800392850
3. M. Hoppentocht, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation Eur. J. Pharm. Biopharm. 86 2013 23 30 10.1016/j.ejpb.2013.10.019
4. S. Vassal, R. Taamma, N. Marty, A. Sardet, P. d'Athis, and F. Brémont Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis Am. J. Infect. Control. 28 2000 347 351 10.1067/mic.2000.110214
5. P.P.H. Le Brun, R.W. Brimicombe, H. van Doorne, and H.G.M. Heijerman The cleaning and disinfection of nebulizers used at home and in a cystic fibrosis centre Eur. Hosp. Pharm. 6 2000 58 63
6. D.E. Geller, M.W. Konstan, J. Smith, S.B. Noonberg, and C. Conrad Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr. Pulm. 42 2007 307 313 10.1002/ppul.20594
7. A. Schuster, C. Haliburn, G. Döring, and M.H. Goldman Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study Thorax 68 2012 344 350 10.1136/thoraxjnl-2012-202059
8. H. Stass, J. Nagelschmitz, S. Willmann, H. Delesen, A. Gupta, and S. Baumann Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study Clin. Drug Investig. 33 2013 419 427 10.1007/s40261-013-0082-0
9. A.S. Dharmadhikari, M. Kabadi, B. Gerety, A.J. Hickey, P.B. Fourie, and E. Nardell Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis Antimicrob. Agents Chemother. 57 2013 2613 2619 10.1128/AAC.02346-12
10. A.H. de Boer, P. Hagedoorn, E.M. Westerman, P.P.H. Le Brun, H.G.M. Heijerman, and H.W. Frijlink Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses Eur. J. Pharm. Sci. 28 2006 171 178 10.1016/j.ejps.2005.11.013
11. E.M. Westerman, A.H. De Boer, P.P.H. Le Brun, D.J. Touw, A.C. Roldaan, and H.W. Frijlink Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study J. Cyst. Fibros. 6 2007 284 292 10.1016/j.jcf.2006.10.010
12. F. Grasmeijer, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Characterisation of high dose aerosols from dry powder inhalers Int. J. Pharm. 437 2012 242 249 10.1016/j.ijpharm.2012.08.020
13. L.V. Sacks, S. Pendle, D. Orlovic, L. Blumberg, and C. Constantinou A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African Hospital Clin. Infect. Dis. 29 1999 96 101 10.1086/520189
14. WHO, Treatment of Tuberculosis Guidelines, 2010.
15. E.A. Nardell, A. Stoltz, A. Dharmadhikari, E. de Kock, M. Mphahlele, M. Hoppentocht, et al., Inhaled colistin: a novel approach for reducing drug-resistant TB transmission, in: S. Poster (Ed.), Int. Union Against Tuberc. Lung Dis., Vancouver, 2013.
16. Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement, Am. J. Respir. Crit. Care Med., vol. 161, 2000, pp. 1376-1395, http://dx.doi.org/10.1164/ajrccm.161.4.16141.
17. M. Hoppentocht, P. Hagedoorn, H.W. Frijlink, and A.H. de Boer Technological and practical challenges of dry powder inhalers and formulations Adv. Drug Deliv. Rev. 75C 2014 18 31 10.1016/j.addr.2014.04.004
18. G.S. Zijlstra, W.L.J. Hinrichs, A.H. de Boer, and H.W. Frijlink The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix Eur. J. Pharm. Sci. 23 2004 139 149 10.1016/j.ejps.2004.06.005
19. P. Begat, D.A. V Morton, J. Shur, P. Kippax, J.N. Staniforth, and R. Price The role of force control agents in high-dose dry powder inhaler formulations J. Pharm. Sci. 98 2009 2770 2783 10.1002/jps.21629
20. R.P. Aquino, L. Prota, G. Auriemma, A. Santoro, T. Mencherini, and G. Colombo Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells Int. J. Pharm. 426 2012 100 107 10.1016/j.ijpharm.2012.01.026
21. K.K. Lam, and J.M. Newton Investigation of applied compression on the adhesion of powders to a substrate surface Powder Technol. 65 1991 167 175 10.1016/0032-5910(91)80179-M
22. B.L. Laube, H.M. Janssens, F.H.C. de Jongh, S.G. Devadason, R. Dhand, and P. Diot What the pulmonary specialist should know about the new inhalation therapies Eur. Respir. J. 37 2011 1308 1417 10.1183/09031936.00166410
23. J. Weers Inhaled antimicrobial therapy - Barriers to effective treatment Adv. Drug Deliv. Rev. 2014 10.1016/j.addr.2014.08.013
24. J.P. de Koning, T.W. van der Mark, P.M.J. Coenegracht, T.F.J. Tromp, and H.W. Frijlink Effect of an external resistance to airflow on the inspiratory flow curve Int. J. Pharm. 234 2002 257 266 10.1016/S0378-5173(01)00969-3
25. M.T. Newhouse, P.H. Hirst, S.P. Duddu, Y.H. Walter, T.E. Tarara, and A.R. Clark Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers Chest 124 2003 360 366 10.1378/chest.124.1.360